Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]Ga-A9-6217 is a Gallium-68 labeled radiopharmaceutical developed by Alpha-9 Theranostics for positron emission tomography (PET) imaging. It is designed to target the Gastrin-Releasing Peptide Receptor (GRPR), a G protein-coupled receptor that is highly expressed in various solid tumors, including prostate, breast, colorectal, and lung cancers. By binding to GRPR, the agent allows for the non-invasive visualization and quantification of receptor density using PET/CT or PET/MRI. This imaging capability is intended to support the diagnosis, staging, and selection of patients for potential GRPR-targeted radioligand therapies. [68Ga]Ga-A9-6217 is currently undergoing Phase 1 clinical evaluation to determine its safety, biodistribution, and dosimetry in patients with advanced or metastatic solid tumors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [68Ga]Ga-A9-6217.